Keeley Teton Advisors LLC Has $1.36 Million Position in Orthofix Medical Inc. $OFIX

Key Points

• Keeley Teton Advisors LLC increased its position in Orthofix Medical Inc. by 36.4% during the first quarter, owning 83,657 shares worth approximately $1.36 million.
• Orthofix Medical has an average rating of Buy from analysts, with a target price of $21.50, following upgrades from several brokerages.
• Despite a quarterly revenue of $203.12 million, Orthofix Medical reported a loss of ($0.36) earnings per share, missing the consensus estimate significantly.

Keeley Teton Advisors LLC increased its position in Orthofix Medical Inc. (NASDAQ:OFIX - Free Report) by 36.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 83,657 shares of the medical device company's stock after acquiring an additional 22,320 shares during the quarter. Keeley Teton Advisors LLC owned about 0.21% of Orthofix Medical worth $1,364,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of OFIX. Wells Fargo & Company MN raised its holdings in Orthofix Medical by 22.8% in the 4th quarter. Wells Fargo & Company MN now owns 24,007 shares of the medical device company's stock worth $419,000 after acquiring an additional 4,462 shares during the period. Invesco Ltd. raised its holdings in Orthofix Medical by 1.0% in the 4th quarter. Invesco Ltd. now owns 74,977 shares of the medical device company's stock worth $1,309,000 after acquiring an additional 767 shares during the period. Renaissance Technologies LLC raised its holdings in Orthofix Medical by 166.9% in the 4th quarter. Renaissance Technologies LLC now owns 82,190 shares of the medical device company's stock worth $1,435,000 after acquiring an additional 51,399 shares during the period. Raymond James Financial Inc. bought a new position in Orthofix Medical in the 4th quarter worth $1,003,000. Finally, Dimensional Fund Advisors LP raised its holdings in Orthofix Medical by 31.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 659,475 shares of the medical device company's stock worth $11,515,000 after acquiring an additional 159,177 shares during the period. Institutional investors own 89.76% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on OFIX. Wall Street Zen upgraded shares of Orthofix Medical from a "sell" rating to a "hold" rating in a report on Saturday, August 9th. JMP Securities reiterated a "market perform" rating on shares of Orthofix Medical in a report on Friday, June 6th. Finally, Barrington Research upgraded shares of Orthofix Medical to a "strong-buy" rating and set a $16.00 price objective on the stock in a report on Monday, June 23rd. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $21.50.

Orthofix Medical Stock Performance

NASDAQ:OFIX opened at $14.51 on Wednesday. The firm's 50-day moving average is $11.89 and its 200-day moving average is $13.54. Orthofix Medical Inc. has a 52-week low of $10.24 and a 52-week high of $20.73. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.50 and a current ratio of 2.67. The company has a market cap of $573.00 million, a price-to-earnings ratio of -4.58 and a beta of 0.82.

Orthofix Medical (NASDAQ:OFIX - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The medical device company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.40). Orthofix Medical had a negative return on equity of 25.43% and a negative net margin of 15.29%.The company had revenue of $203.12 million for the quarter, compared to the consensus estimate of $196.89 million. Orthofix Medical has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Orthofix Medical Inc. will post -2.81 earnings per share for the current year.

Insider Buying and Selling

In other Orthofix Medical news, insider Aviva Mcpherron sold 3,728 shares of the firm's stock in a transaction dated Wednesday, June 18th. The shares were sold at an average price of $10.51, for a total transaction of $39,181.28. Following the completion of the transaction, the insider owned 46,322 shares in the company, valued at $486,844.22. This trade represents a 7.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.30% of the stock is currently owned by corporate insiders.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.

Want to see what other hedge funds are holding OFIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Orthofix Medical Inc. (NASDAQ:OFIX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.